BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
2018; American Association for Cancer Research; Volume: 9; Issue: 2 Linguagem: Inglês
10.1158/2159-8290.cd-18-0715
ISSN2159-8290
AutoresKevin Lin, Maria I. Harrell, Amit M. Oza, Ana Oaknin, Isabelle Ray‐Coquard, Anna V. Tinker, Elena Helman, Marc R. Radke, Carmen Say, Lan-Thanh Vo, Elaina Mann, Jeffrey D. Isaacson, Lara Maloney, David M. O’Malley, Setsuko K. Chambers, Scott H. Kaufmann, Clare L. Scott, Gottfried E. Konecny, Robert L. Coleman, James Sun, Heidi Giordano, James D. Brenton, Thomas C. Harding, Iain A. McNeish, Elizabeth M. Swisher,
Tópico(s)CRISPR and Genetic Engineering
ResumoA key resistance mechanism to platinum-based chemotherapies and PARP inhibitors in
Referência(s)